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ABSTRACT 
iii 
A decrease in astrocyte function and viability has been linked to many neurodegenerative 
diseases, including schizophrenia, major depressive disorders, Alzheimer’s disease, and 
Amyotrophic Lateral Sclerosis (ALS). Previous research indicates that some estrogens may have 
a positive effect on neuron and astrocyte viability. Estrogens’ effects on the brain are of interest 
as estrogens are commonly prescribed as hormone replacement therapy to reduce the symptoms 
of menopause in women. Unfortunately, these effects on are not completely understood. The 
goal of the project was to discover if estrogen has any protective effect on astrocytes exposed to 
oxidative stress. We measured the oxidative stress level of N1 1321 glial cells that were exposed 
to 600pM hydrogen peroxide. The astrocytes were pretreated for one hour with one of four types 
of estrogen at four concentrations ranging ffomlOnM - IOJIM. Two endogenous human 
estrogens, 17 alpha-estradiol and 17 beta-estradiol, and two equine estrogens, equilin and 
equilenin, were utilized. Only 17 alpha-estradiol showed a statistical difference in the oxidative 
stress levels of astrocytes. However, the results indicate that differing estrogen concentration still 
had no effect on the oxidative stress levels in unstressed astrocyte populations. 
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INTRODUCTION 
The importance of glial cells in the brain cannot be overstated. Glial cells function to 
support neurons and comprise as much as 90% of the human brain (He and Sun, 2006). One of 
the most common glial cells is the stellate-shaped astrocyte cell. Astrocytes have a variety of 
essential functions in the central nervous system (CNS). As one function, astrocytes sustain 
neurons by providing glycogen as a source of energy to fuel neurons (Reynolds, 2012). 
In addition to providing crucial energy and nourishment, astrocytes are employed in a 
multitude of other crucial brain functions related to sustainability. Notably, astrocytes are 
involved in the maintenance of the extracellular ion concentration in the CNS, preserving the 
permeable membrane known as the blood-brain barrier, and assisting in the repair and 
regeneration of nervous tissue after an injury (Venkatesh et al., 2013). Astrocytes have also been 
shown to be involved in neuronal migration by providing a natural scaffolding for neurons 
(Venkatesh et al., 2013). Additionally, astrocytes have been associated with the reuptake of 
neurotransmitters and the release of gliotransmitters in the brain (Agulhon et al., 2010). 
Furthermore, astrocytes have been shown to assist with synaptogenesis by releasing proteins, 
which help to increase the number of synapses formed between neurons (Barker and Ullian, 
2008). Finally, there is even evidence that astrocytes of the subventricular zone may act as neural 
stem cells. These astrocytes have been shown to be precursor cells to neuroblasts and ultimately 
new neurons (Doetsch et al., 1999). Undoubtedly, astrocytes have numerous supportive functions 
to nervous tissue. 
Because astrocytes play such fundamental functions in the brain, it is not surprising that a 
decrease in their function and viability has been linked to multiple neurological diseases. For 
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instance, reduced astrocyte function has been connected to schizophrenia and other major 
depressive disorders (Barres and Sloan, 2014). Also, a decline in astrocyte function has been 
linked to many neurodegenerative diseases. In one example, Alzheimer’s disease, astrocyte 
function is diminished by the accumulation of amyloid-P plaques, which eventually leads to 
astrocyte cell death (Maragakis and Rothstein, 2006). In addition, Amyotrophic Lateral Sclerosis 
(ALS) is associated with the loss of an astrocyte glutamate transporter, and Huntington’s disease 
is linked to the alteration of astrocyte gap junctions. Astrocyte deficiency has also been 
associated with both Alexander disease and Parkinson’s disease (Maragakis and Rothstein, 
2006). 
Noticeably, astrocytes play an important role in the neural functioning as evidenced by 
the quantity of astrocytes in the CNS, the critical functions astrocytes contribute to neurons, and 
the significant association of deteriorating astrocytes in neurodegenerative diseases. With this in 
mind, it was of interest to study biological components that could increase or decrease the 
viability of astrocytes. One such biological component of interest is the effect estrogen has on 
astrocytes, and in particular, the effect that estrogen has on the oxidative stress levels in 
astrocytes. 
Estrogen’s effects on the brain are of interest for two major reasons. First, estrogen’s 
effects on the brain are not yet completely understood, and second, estrogen is commonly 
prescribed in hormone replacement therapy to reduce the symptoms of menopause in women. 
According to the Mayo Clinic, menopause is a biological transformation period in women 
characterized by decreased estrogen levels and is identified with an ending of both the menstrual 
cycle and fertility. The progression into menopause is frequently associated with numerous 
uncomfortable symptoms including hot flashes, sleeping problems, fatigue, mood changes, and 
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increased urogenital sensitivity and dryness (Mehra 2014). To lessen these uncomfortable 
symptoms, many women elect to take estrogen replacement therapy as a practical remedy. The 
Mayo Clinic defines hormone replacement therapy as the addition of supplemental, 
pharmaceutically produced hormones to replenish the natural hormones that the body no longer 
naturally produces. However, the use of estrogen replacement therapy has been correlated with 
both health benefits and detriments in different studies. Because estrogen’s effects on the brain 
are not completely understood, the use of estrogen replacement therapy is controversial. The 
controversy and contrasting results could conceivably stem from the type of estrogen used in 
therapy, rather than all estrogen therapy. 
Currently, menopausal symptoms are reduced through the use of Premarin, a drug 
produced by Pfizer pharmaceutical company for estrogen replacement therapy. Premarin is 
composed of equine estrogens, derived from pregnant mare urine. Specifically, Premarin is 
comprised of two types of conjugated equine estrogens (CEEs), which include equilin and 
equilenin. However, these equine estrogens are not naturally occurring in humans and the effects 
of CEEs are largely unknown. There have been contending views in the literature regarding the 
effects of CEEs. For instance, in healthy women, CEEs have been reported to increase the risk of 
ischemic stroke (Hendrix et al. 2006). However, the combination of multiple CEEs has also been 
shown to have neuroprotective effects (Zhao and Brinton, 2006). Ultimately, the use of CEEs is 
currently controversial as it is unknown if the effects are beneficial or detrimental to women. 
While CEEs are not naturally occurring in humans, there are three types of estrogens that 
naturally occur in humans. These endogenous human estrogens include estrone (El), estriol (E3), 
and the most common, estradiol (E2). One particular isomer of estradiol, 17 beta-estradiol (E2), 
has been associated with neuroprotective and cardioprotective properties. Specifically, 17 beta- 
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estradiol has been found to be neuroprotective in multiple ways. First, 17 beta-estradiol has been 
shown to have apparent antioxidant properties that work to reduce oxidative stress in the brain 
(Behl et al. 1997). Also, 17 beta-estradiol has also been revealed to protect the brain, and 
specifically protect astrocytes, from ischemic injuries. This is thought to be due to 17 beta- 
estradiol’s ability to reduce the harmful effects of oxygen and glucose deprivation (Guo et al., 
2012). One other estradiol isomer, 17 alpha-estradiol, has also displayed neuroprotective effects 
similar to those of 17 beta-estradiol. In particular, 17 alpha-estradiol is effective in reducing 
symptoms in both Alzheimer’s and Parkinson’s disease as well showing subsequent usefulness 
following a stroke (Dykens et al., 2005). Moreover, the 17 alpha-estradiol isomer has even been 
shown to increase neurogenesis and positively influence cell proliferation in a dose-dependent 
manner (Barha et al., 2009). In essence, both 17 beta-estradiol and 17 alpha-estradiol have 
demonstrated neuroprotective benefits. 
The purpose of this study was to discover if different types of estrogens have either a 
protective or detrimental effect on astrocyte cells that are exposed to oxidative stressful 
conditions. Astrocytes were pretreated with estrogen for one hour, subsequently exposed to 
oxidative stress, and then finally retreated with estrogen for two hours. These relatively shorter 
estrogen treatments were chosen in order to determine if estrogen has an effect via a rapid 
signaling pathway or a slower signaling pathway influencing transcription or translation. A 
transcriptional or translational change would require a longer estrogen exposure time (possibly 
between 24 - 48 hours) for estrogen to show an effect on astrocytes. 
Also in this study, astrocytes were treated with either endogenous estrogens, which are 
naturally occurring in humans or CEEs, which are not naturally occurring in humans, but are 
often prescribed to post-menopausal women to combat the symptoms of menopause. This 
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allowed us to discover if naturally occurring estrogens have similar or different effects when 
compared with CEEs. The two endogenous human estrogens tested included: 17 alpha-estradiol, 
17 beta-estradiol and the two conjugated equine estrogens tested included: equilin, and equilenin. 
The four estrogens were also assessed at four different concentrations between lOnM -10p.M. 
This allowed us to determine whether the estrogen concentration had an effect on oxidative stress 
levels in astrocytes. 
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METHODS 
Cells 
In this study, we used GIBCO® Human Astrocytes (N1 1321), which are a human-based 
astrocyte cell line sold by Life Technologies. The human astrocytes arrived cryopreserved in 
liquid nitrogen. The initial portion of the experiment entailed preparing the culture of astrocyte 
cells. The astrocytes were thawed in a water bath at 37°C. The cells were then placed in a T-75 
flask culture vessel with 10 microliters Dulbecco’s Modified Eagle’s Medium (DMEM), a 
complete astrocyte medium which also contained 10% Fetal Bovine Serum (FBS) and a 1% 
antibiotic/antimycotic that was supplemented to the astrocyte media. The media was changed 
approximately every two days. The culture vessel was incubated at 37°C in an atmosphere 
containing 5% CO2. Incubation continued until cells became roughly 80-90% confluent, which 
was determined using a microscope. Once confluent, the astrocytes were subcultured using 5 
microliters trypsin-EDTA to free cells from the substrate. Next, using a Bio-Rad automated cell 
counter, the concentration of cells in solution was adjusted to lxl 06 cells/mL. Finally, 200 
microliters of the astrocyte solution was placed in 34 wells of a 96 well plate. Table 1 
summarizes the treatment design for different astrocyte populations. 
Astrocyte Treatment 
The second portion of the experiment entailed pre-treating astrocytes, in vitro, with the 
four hormones: 17 alpha-estradiol, 17 beta-estradiol, equilin, and equilenin. The astrocytes were 
pretreated with 10 microliters of the estrogens for a final concentration of lOnM, lOOnM, 1 pM, 
or 1 OpM. There was also a positive and negative control group of astrocytes, which were not pre- 
treated with any estrogen. Next, half of the astrocytes were exposed to oxidative stress for one 
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hour by adding 20 microliters hydrogen peroxide for a final concentration of 600 uM The other 
half of the wells received 20 microliters PBS as a control. After one hour, all liquid was removed 
and 200 microliters of fresh astrocyte media was added. The same astrocytes, which were 
pretreated with the four estrogen concentrations earlier, were then again retreated with 10 
microliters of their respective estrogen solutions and incubated for two more hours. 
Oxidative Stress Assay 
The last aspect of the experiment involved testing the astrocytes for oxidative stress using 
flow cytometry on the Muse® system. To accomplish this, astrocytes were first removed from 
each well by adding 100 microliters of trypsin-EDTA per well. Once removed, the astrocytes 
were placed in centrifuge tubes containing 100 microliters of fresh media and centrifuged at 
3000 rpm for three minutes. Next, all liquid was removed from the centrifuge tubes, and the 
astrocytes were resuspended in 100 microliters of Muse® assay buffer. Then 10 microliters of 
that resuspended cellular solution was added to 190 microliters of prepared Muse® working 
solution, which allows the Muse® system flow cytometry assay to detect any reactive oxygen 
species. Finally, the prepared working solution, now containing the astrocytes, was incubated for 
thirty more minutes, and then each sample was tested via an oxidative stress assay on the Muse® 
system using flow cytometry. 
Statistical Analysis 
The independent variables were +/- hydrogen peroxide treatment and the concentration of 
estrogen. In total, there were five trials. Statistical significance of oxidative stress and estrogen 
concentration was assessed, for each estrogen, using a two-way ANOVA and LSD post hoc test. 
A p-value <0.05 indicated statistical significance. 
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RESULTS 
There was not a significant difference between the positive control of astrocytes stressed 
with hydrogen peroxide and the negative control of unstressed astrocytes (1-way ANOVA, 
Stressed, Fi,g=0.508, P=0.496; Figure 1). The 17 alpha-estradiol assay did show a statistically 
significant difference when comparing estrogen treatment. However, there was no statistical 
significant difference across the four concentrations of 17 alpha-estradiol used (2-way ANOVA, 
Stressed, Fi,32=7.670, P=0.009; Concentration, F3,32=0.046, P=0.987; Figure 2). Next, in the 17 
beta-estradiol assay, there was not a statistically significant difference between the stressed and 
unstressed cells, and there was also no statistical significant difference across the four 
concentrations of 17 beta-estradiol used (2-Way ANOVA, Stressed, Fi,32=3.001, P=0.093; 
Concentration, F3,32=1.863, P=0.156; Figure 3). In the equilin assay, there was no statistical 
significance between oxidative stress levels of the stressed and unstressed cells, and there was not a 
statistical significance across the four concentrations of equilin used (2-way ANOVA, Stressed, 
Fi,32=0.067, P=0.797; Concentration, F3,32=0.148, P=0.930; Figure 4). Finally, in the equilenin 
assay, there was again no statistical significance between the stressed and unstressed cells, and 
there was not a statistical significance among the four concentrations of equilenin used. (2-way 
ANOVA, Stressed, Fi,32=1.147, P=0.292; Concentration, F3,32=1.417, P=0.256; Figure 5). 
9 
DISCUSSION 
In summary, the results showed no significant difference across the four different 
estrogen concentrations utilized, between lOnM-lOpM. In addition, the results showed only the 
17 alpha-estradiol assay had a statistically significant difference in oxidative stress levels across 
the different estrogen concentrations when comparing astrocytes which received a 600 pM 
hydrogen peroxide treatment and astrocytes which did not receive any hydrogen peroxide. This 
may indicate that there may be an additive negative interaction when combining 17 alpha- 
estradiol and hydrogen peroxide. Future studies should test to see if this is valid. Finally, there 
was no significant difference between the oxidative stress levels of the positive control, in which 
astrocytes were exposed to hydrogen peroxide, and the negative control, in which astrocytes 
were not exposed to hydrogen peroxide. 
The absence of a significant difference between the positive and negative controls could 
be the result of a couple factors. First, it is possible the one hour hydrogen peroxide exposure 
time was not long enough to significantly stress the astrocytes. It is also possible the 600 pM 
concentration is not concentrated enough to induce stress to the astrocytes. However, this seems 
unlikely as a previous study by Grimes and Hughes showed a one hour treatment with 600 pM 
hydrogen peroxide to successfully stress astrocytes (2015). Therefore, it is more likely that 
another factor is responsible for the inconsistency. Specifically, it is hypothesized that trypsin is 
responsible for the discrepancy. Trypsin is a proteolytic enzyme used to lyse cadherin molecules 
involved in cell adhesion (Descargues et al., 2006). Therefore, in this study, trypsin was used to 
facilitate the dissociation of astrocytes both from other astrocytes as well as the culture substrate. 
However, trypsin has been shown to lyse other cell surface proteins, which eventually leads to 
the deterioration of cells (Huang et al., 2010). Thus, it is thought that trypsin, itself, is stressful to 
cells and could induce oxidative stress in astrocytes. Unfortunately, the trypsin exposure time 
was not as tightly controlled as was hoped, and different trials required different trypsin exposure 
periods for dissociation and eventual removal of the astrocytes. In future studies, a different 
removal method is recommended, if possible, or a very tight control of trypsin exposure. 
Seeing as there was not a significant difference in oxidative stress levels between the 
positive and negative controls, it is still largely unknown if short term estrogen exposures have 
protective effects on astrocytes exposed to oxidative stressful conditions. However, even with the 
external oxidative stress induction being unsuccessful, the results still suggest one meaningful 
conclusion. Even in those relatively unstressed astrocytes, which were not exposed to any 
purposeful induction of oxidative stress, there is always some natural oxidative stress present. 
Therefore, the results indicate that modifying estrogen concentrations has no effect on the 
oxidative stress levels in the unstressed astrocyte populations. Accordingly, it is possible that 
estrogen does not have an effect on oxidative stress with a relatively shorter treatment time of 
one or two hours. 
Assuming that estrogen did not have an effect on oxidative stress levels in astrocytes, it is 
possible that estrogen is neuroprotective to astrocytes for alternative reasons. One possible 
alternative is that estrogen is neuroprotective by reducing apoptosis in astrocytes. One such study 
has shown estradiol to have this capability by upregulating expression of the bcl-2 gene, a gene 
known to decrease apoptosis, especially after ischemic injuries (Dubai et al., 1999). This is 
further supported by Grimes and Hughes, in which they showed both 17 beta-estradiol and 
equine estrogens to be effective in reducing hydrogen peroxide induced apoptosis. Although, in 
that study, the astrocyte cell line originated from mouse cerebellum (C8-D1 A), instead of the 
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human astrocyte cell line used in our study. Additionally, estrogen has also been shown to be 
protective by increasing expression of certain cytokine molecules. For instance, estradiol has 
been shown to upregulate the expression and secretion of transforming growth factor-P (TGF-P), 
a cytokine molecule with known neuroprotective benefits (Dhandapani et al., 2005). Finally, 
estrogens may be neuroprotective by upregulating expression of the glutamine synthetase gene in 
astrocytes (Mong and Blutstein, 2006). This gene is critical in astrocytes as it increases 
glutamine production, which is necessary for neuronal survival (Mong and Blutstein, 2006). 
Therefore, there are a number of alternative mechanisms, besides reducing oxidative stress, in 
which estrogens are thought to protect astrocytes. 
Finally, it is of relevance to discuss estrogen’s possible signaling pathways. Estrogen, a 
lipid steroid molecule, follows one of two possible signaling pathways after it diffuses into the 
cell. First, there is a non-genomic signaling pathway, in which estrogen binds to the G protein- 
coupled receptor, GPR30, inducing a release of calcium ions from the endoplasmic reticulum 
(Weatherman, 2006). By employing the one hour estrogen pretreatment, we sought to discover if 
estrogen is neuroprotective via some rapid signaling pathway, such as this. However, it is also 
possible that estrogen is neuroprotective via a genomic signaling pathway. For instance, in an 
alternative signaling pathway estrogen has been shown to influence ligand activated transcription 
by binding to the ERa and ERP receptors inside the cell (Weatherman, 2006). These 
transcriptional effects require more time and thus would not show up with the one hour estrogen 
pretreatment. Considering this, further inquiry into the effects of longer estrogen treatment times 
should be explored, such as a 24-48 hour pretreatment with estrogen. Altogether, more research 
is required to elucidate estrogen’s effects on astrocyte cells. 
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Table 1. The treatment design depicting the 34 different populations of astrocytes cultured in a 
96 well plate. Each estrogen was tested at four concentrations: lOnM, lOOnM, lpM, lOpM. One 
half of the astrocytes were exposed to 600 pM H2O2. Finally, there were two control groups 
without any estrogen. There was one negative control astrocyte population without H2O2 
exposure, and another positive control astrocyte population that was exposed to H2O2. 
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